Daratumumab

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2250 publications

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Journal: Future oncology (London, England)
Published: April 13, 2026

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Journal: The New England journal of medicine
Published: April 08, 2026

Mesenteric AL Amyloidosis with Diffuse Calcifications: A Case Report and Review of the Literature.

Mesenteric AL Amyloidosis with Diffuse Calcifications: A Case Report and Review of the Literature.

Journal: Internal medicine (Tokyo, Japan)
Published: April 08, 2026

Recurrent CMV Retinitis in a Daratumumab-Treated Multiple Myeloma Patient With Systemic Antiviral Intolerance.

Recurrent CMV Retinitis in a Daratumumab-Treated Multiple Myeloma Patient With Systemic Antiviral Intolerance.

Journal: Retinal cases & brief reports
Published: April 07, 2026

Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.

Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.

Journal: Hematology (Amsterdam, Netherlands)
Published: April 03, 2026

A rare case of renal cancer with PLA2R-positive membranous nephropathy and AL amyloidosis: Insights into mechanisms and treatment.

A rare case of renal cancer with PLA2R-positive membranous nephropathy and AL amyloidosis: Insights into mechanisms and treatment.

Journal: Clinical nephrology
Published: March 25, 2026

Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM: The MajesTEC-3 trial is the first to test a combination of a bispecific antibody in the setting of first to third relapse after initial treatment for multiple myeloma.

Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM: The MajesTEC-3 trial is the first to test a combination of a bispecific antibody in the setting of first to third relapse after initial treatment for multiple myeloma.

Journal: Cancer
Published: March 20, 2026

Daratumumab induced lichenoid drug eruption.

Daratumumab induced lichenoid drug eruption.

Journal: JAAD case reports
Published: March 20, 2026

Early intervention for high-risk smoldering multiple myeloma (SMM).

Early intervention for high-risk smoldering multiple myeloma (SMM).

Journal: The Cochrane database of systematic reviews
Published: March 18, 2026

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

Journal: Expert opinion on biological therapy
Published: March 17, 2026

CD38-Targeted Small-Molecule PET Radiotracer for Noninvasive Tumor Evaluation and Preliminary Therapy Monitoring in Multiple Myeloma.

CD38-Targeted Small-Molecule PET Radiotracer for Noninvasive Tumor Evaluation and Preliminary Therapy Monitoring in Multiple Myeloma.

Journal: Journal of medicinal chemistry
Published: March 16, 2026

Daratumumab for Treatment of Refractory Podocytopathy: A Case Report.

Daratumumab for Treatment of Refractory Podocytopathy: A Case Report.

Journal: Kidney medicine
Published: March 05, 2026
Showing 1-12 of 2,250

Last Updated: 04/28/2026